Thymosin Alpha-1 (Ta1) is a 28-amino acid peptide originally isolated from thymosin fraction 5, a thymus gland extract, by Dr. Allan Goldstein at George Washington University in the 1970s. It is one of the most clinically validated immune-modulating peptides, with regulatory approval in over 35 countries (as Zadaxin) for hepatitis B and as an immune adjuvant. Ta1 plays a central role in T-cell maturation and immune system homeostasis.

Thymosin Alpha-1 acts on toll-like receptors (TLR2, TLR9) on dendritic cells and innate immune cells, enhancing antigen presentation and stimulating both innate and adaptive immunity. It promotes T-cell differentiation from thymocyte precursors, enhances NK cell cytotoxicity, increases IL-2 and IFN-alpha production, and restores T-helper cell balance. It also activates indoleamine 2,3-dioxygenase (IDO), modulating immune tolerance and preventing excessive inflammatory responses.

• Improved survival in chronic hepatitis B patients when combined with interferon therapy (Andreone et al., 2001)
• Enhanced immune reconstitution in HIV-positive patients in clinical studies
• Showed efficacy as vaccine adjuvant, improving antibody response in elderly and immunocompromised populations
• Demonstrated anti-tumor immune effects by enhancing dendritic cell maturation and T-cell activation
• Improved outcomes in severe sepsis by restoring T-cell function and reducing inflammatory cytokine storms (Wu et al., 2013)

1. Thymosin alpha 1 for the treatment of chronic hepatitis B
   Expert Opin Biol Ther, 2001
2. Thymosin alpha 1 — a review of clinical applications
   Ann N Y Acad Sci, 2007
3. Thymosin alpha 1 as adjunctive therapy for sepsis
   Crit Care Med, 2013

Available for Research

Lab-tested, third-party COA published, U.S. ships same day.